Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.51 |
| ▸ | ALPL | P05186 | 10/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RPA1 | P27694 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002378 | 0.86 | HCAR3 (0.37) | HCAR3ALPLTP53HCAR2ALOX15 | |
| SCHEMBL20665563 | 0.86 | HCAR3 (0.37) | HCAR3ALPLTP53HCAR2 | |
| SCHEMBL15651990 | 0.84 | PLA2G10 (0.41) | HCAR3ALPLTP53 | |
| SCHEMBL6110152 | 0.84 | HCAR3 (0.45) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL19049344 | 0.83 | HCAR3 (0.39) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL18997400 | 0.81 | HCAR3 (0.35) | HCAR3ALPLTP53HCAR2 | |
| SCHEMBL21776407 | 0.80 | HCAR3 (0.34) | HCAR3ALPLTP53 | |
| SCHEMBL1431995 | 0.79 | ALPL (0.54) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL6110120 | 0.79 | HCAR3 (0.42) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL5599286 | 0.79 | HCAR3 (0.46) | HCAR3ALPLCA9CA12TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| EP-2261210-B1 | 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE | MSD KK (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8367698-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | NAGASE TSUYOSHI (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8188280-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | MSD K.K. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2261210-A1 | 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR3 347/4885ALPL 1586/4885CA9 874/4885 |
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | HCAR3 272/4885ALPL 4057/4885CA9 2709/4885 |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | HCAR3 2618/4885ALPL 3465/4885CA9 2732/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR3 347/4885ALPL 1586/4885CA9 874/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR3 347/4885ALPL 1586/4885CA9 874/4885 |
| US-11124502-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR3 347/4885ALPL 1586/4885CA9 874/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR3 347/4885ALPL 1586/4885CA9 874/4885 |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | HCAR3 272/4885ALPL 4057/4885CA9 2709/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR3 347/4885ALPL 1586/4885CA9 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.